Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney disease

Pediatric Nephrology

Volumn 30, Issue 5, 2015, Pages 811-819

  Makulska, Irena ^a   Szczepańska, Maria ^b   Drożdż, Dorota ^c   Polak Jonkisz, Dorota ^a   Zwolińska, Danuta ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Children; Chronic kidney disease; Dialysis; Intima media thickness; Markers of endothelial damage; Skin autofluorescence

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER;

ADOLESCENT; CHILD; CHRONIC KIDNEY FAILURE; COMPLICATION; FEMALE; FLUORESCENCE IMAGING; HUMAN; MALE; PATHOLOGY; PROCEDURES; SKIN; VASCULAR DISEASES;

ADOLESCENT; BIOMARKERS; CHILD; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; OPTICAL IMAGING; RENAL INSUFFICIENCY, CHRONIC; SKIN; VASCULAR DISEASES;

EID: 84928257941     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-014-2997-y     Document Type: Article

References (50)

1. Groothoff JW, Lilien MR, van de Kar NCAJ, Wolff ED, Davin JC (2005) Cardiovascular disease as a late complication of end-stage renal disease in children. Pediatr Nephrol 20:374–379
2. Litwin M, Grenda R, Prokurat S, Abuauba M, Latoszyka J, Jobs K, Boguszewska-Bączkowska A, Wawer ZT (2001) Survival and causes of death among children on hemodialysis and peritoneal dialysis. Pediatr Nephrol 16:996–1001
3. Parekh RS, Carrol CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191–197
4. Semba RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L (2009) Serum carboxymethyl-lysine an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens 22:74–79
5. Suliman ME, Heimbürger O, Bárány P, Anderstam B, Pecoits-Filho R, Rodríguez Ayala E, Qureshi AR, Fehrman-Ekholm I, Lindholm B, Stenvinkel P (2003) Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patent starting on dialysis therapy. J Am Soc Nephrol 14:1614–1622
6. Zwolińska D, Grzeszczak W, Szczepańska M, Kiliś-Pstrusińska K, Szprynger K (2006) Lipid peroxidation and antioxidant enzymes in children on maintenance dialysis. Pediatr Nephrol 21:705–710
7. Zwolińska D, Grzeszczak W, Szczepańska M, Kiliś-Pstrusińska K, Szprynger K (2006) Vitamin A, E and C as non enzymatic antioxidants and their relation to lipid peroxidation in children with chronic renal failure. Nephron Clin Pract 103:c12–c18
8. Nishizawa Y, Koyama H, Inaba M (2012) AGEs and cardiovascular diseases in patients with end-stage renal disease. J Ren Nutr 22:128–133
9. Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S, Vienken J (2001) Influence of dialysis modalities on serum AGEs levels in end-stage renal disease patients. Nephrol Dial Transplant 16:999–1008
10. McIntyre NJ, Chesterton LJ, John SG, Jefferies HJ, Burton JO, Taal MW, Fluck RJ, McIntyre CW (2010) Tissue-advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol 5:51–55
11. Rodríguez-Ayala E, Anderstam B, Suliman ME, Seeberger A, Heimbürger O, Lindholm B, Stenvinkel P (2005) Enhanced RAGE-mediated NF kappa-B stimulation in inflammed hemodialysis patients. Atherosclerosis 180:333–340
12. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG (2001) Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104:1464–1470
13. Ueno H, Koyama H, Fukumoto S, Tanaka S, Shoji T, Shoji T, Emoto M, Tahara H, Inaba M, Kakiya R, Tabata T, Miyata T, Nishizawa Y (2011) Advanced glycation end products, carotid atherosclerosis and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism 60:453–459
14. Makulska I, Szczepańska M, Drożdż D, Polak-Jonkisz D, Zwolińska D (2013) Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease. Pediatr Nephrol 28:121–128
15. Herbrig K, Pistrosch F, Oelschlaegel U, Wichmann G, Wagner A, Foerster S, Richter S, Gross P, Passauer J (2004) Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis 11:310–318
16. Hartog JW, Gross S, Oterdoom LH, van Ree RM, de Vries AP, Smit AJ, Schouten JP, Nawroth PP, Gans RO, van Son WJ, Bierhaus A, Bakker SJ (2009) Skin-autofluorescence an independent predictor of graft loss in renal transplant recipients. Transplantation 87:1069–1077
17. Foundation NK (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39[2 Suppl 1]:S1–S266
18. Schwartz GJ, Gauthier B (1985) A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 106:522–526
19. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576
20. Meerwaldt R, Oomen PHN, Links TP, Gans ROB, Smit AJ, Graaff R (2004) Simple noninvasive assessment of advanced glycation endproduct accumulation. Diabetologia 47:1324–1330
21. Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1–9
22. Miyata T, Kurokawa K, Van Ypersele De Strihou C (2000) Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 11:1744–1752
23. Miyata T, Van Ypersele De Strihou C, Kurokawa K, Baynes JW (1999) Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications. Kidney Int 55:389–399
24. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:875–886
25. Ueno H, Koyama H, Tanaka S, Fukumoto S, Shinohara K, Shoji T, Emoto M, Tahara H, Kakiya R, Tabata T, Miyata T, Nishizawa Y (2008) Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metab Clin Exp 57:1452–1457
26. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, Smit AJ (2007) Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30:107–112
27. Hartog JW, Hummel YM, Voors AA, Schalkwijk CG, Miyata T, Huisman RM, Smit AJ, Van Veldhuisen DJ (2008) Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J Card Fail 14:596–602
28. Sebecova K, Podracka L, Heidland A, Schinzel R (2001) Enhanced plasma of advanced glycation end products (AGE) and pro-inflammatory cytocines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation- are they inter-related? Clin Nephrol 56:S21–S26
29. Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smilde TD, Damman K, Bakker SJ, Smit AJ, van Veldhuisen DJ (2007) Clinical and prognostic value of advanced glycation end products in chronic heart failure. Eur Heart J 28:2879–2885
30. Nishizawa Y, Shoji T, Maekawa K, Nagasue K, Okuno S, Kim M, Emoto M, Ishimura E, Nakatani T, Miki T, Inaba M (2003) Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 41:S76–S79
31. Tanaka K, Katoh T, Asai J, Nemoto F, Suzuki H, Asahi K, Sato K, Sakaue M, Miyata T, Watanabe T (2009) Relationship of skin autofluorescence to cardiovascular disease in Japanese hemodialysis patients. Ther Apher Dial 14:334–340
32. Testa A, Benedetto FA, Spoto B, Pisano A, Tripepi G, Mallamaci F, Malatino LS, Zoccali C (2006) The E-selectin gene polymorphism and carotid atherosclerosis In end-stage renal disease. Nephrol Dial Transplant 21:1921–1926
33. Bonomini M, Reale M, Santarelli P, Stuard S, Settefrati N, Albertazzi A (1998) Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron 79:399–407
34. Musiał K, Szprynger K, Szczepańska M, Zwolińska D (2009) Heat shock protein in children and young adults on chronic hemodialysis. Pediatr Nephrol 24:2029–2034
35. El Messal M, Beaudeux JL, Drissi A, Giral P, Chater R, Bruckert E, Adlouni A, Chapman MJ (2006) Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia. Clin Chim Acta 366:185–189
36. Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, Clark LL, Stroud RE, Corn WC, Finklea L, Zile MR, Spinale FG (2006) Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 114:1020–1027
37. Fernandez-Fresnedo G, Rodrigo E, de Francisco AL, de Castro SS, Castañeda O, Arias M (2006) Role of pulse pressure on cardiovascular RSC in chronic kidney disease patients. J Am Soc Nephrol 17:S246–S249
38. Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M, Bertazzoni G, Gazzaniga PP, Alessandri C (2003) Serum metalloproteinase-9 levels in patient with coronary artery disease: a novel marker of inflammation. J Investig Med 51:295–300
39. Fitzsimmons PJ, Forough R, Lawrence ME, Gantt DS, Rajab MH, Kim H, Weylie B, Spiekerman AM, Dehmer GJ (2006) Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease. Atherosclerosis 194:196–203
40. Brooks ER, Langman CB, Wang S, Price HE, Hodges AL, Darling L, Yang AZ, Smith FA (2009) Methylated arginine derivatives in children and adolescents with chronic kidney disease. Pediatr Nephrol 24:129–134
41. Wang S, Vincente FB, Miller A, Brooks ER, Price HE, Smith FA (2007) Measurement of arginine derivatives in pediatric patients with chronic kidney disease using high-performance liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 45:1305–1312
42. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D (2000) Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 96:4212–4215
43. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak N, Nagamine Y (1999) The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56:104–132
44. Addabbo F, Mallamaci F, Leonardis D, Tripeppi R, Tripeppi G, Goligorsky MS, Zoccali C (2007) Searching for biomarker patterns characterizing carotid atherosclerotic burden In patients with reduced renal function. Nephrol Dial Transplant 22:3521–3526
45. Peng Y, Liu H, Liu F, Ouyang L, Cheng M, Gao L, Pan F, Liu Y, Chen X, Li J (2008) Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic hemodialysis patients. Nephrology 13:579–586
46. Segarra A, Chacon P, Martinez-Eyarre C, Argelaguer X, Vila J, Ruiz P, Fort J, Bartolome J, Camps J, Moliner E, Pelegri A, Marco F, Olmos A, Piera L (2001) Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 12:1255–1263
47. Molino D, De Santo NG, Marotta R, Anastasio P, Mosavat M, De Lucia D (2004) Plasma levels of plasminogen activator inhibitor type-1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin and antiprothrombin antibodies are risk factors for thrombosis In hemodialysis patients. Semin Nephrol 24:495–501
48. Małyszko J, Małyszko JS, Koźmiński P, Pawlak K, Myśliwiec M (2008) Adipokines, linking adipocytes and vascular function in hemodialysed patients, may also be possibly related to CD146, a novel adhesion molecule. Clin Appl Thromb Hemost 14:338–345
49. Smit AJ, Lutgers HL (2004) The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 11:2767–2784
50. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB (2012) Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 11:131–136